Study of Octanorm Subcutaneous IG in Patients With PID
NCT01888484
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immune Deficiency Disorder
Interventions
BIOLOGICAL:
octanorm 16.5%
Sponsor
Octapharma